Quick Answer
Jazz Pharmaceuticals plc reported Operating Income of -$430.24 million for fiscal year 2025.
Jazz Pharmaceuticals plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$430.24M | -160.0% |
| 2024 | $716.63M | +23.9% |
| 2023 | $578.58M | +983.0% |
| 2022 | -$65.53M | -138.5% |
| 2021 | $170.28M | -55.0% |
| 2020 | $378.07M | -29.0% |
| 2019 | $532.37M | -13.4% |
| 2018 | $614.84M | +16.3% |
| 2017 | $528.84M | -10.6% |
| 2016 | $591.65M | +16.4% |
| 2015 | $508.22M | +159.8% |
| 2014 | $195.59M | -42.5% |
| 2013 | $340.31M | +72.0% |
| 2012 | $197.84M | +54.8% |
| 2011 | $127.83M | +121.2% |
| 2010 | $57.79M | +262.8% |
| 2009 | $15.93M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $57.51M | -77.9% | +108.4% |
| June 30, 2025 | -$686.39M | -444.2% | -1128.1% |
| March 31, 2025 | -$55.89M | -184.4% | -121.5% |
| September 30, 2024 | $260.21M | +50.9% | +30.5% |
| June 30, 2024 | $199.44M | +26.5% | +201.2% |
| March 31, 2024 | $66.21M | -47.5% | -61.6% |
| September 30, 2023 | $172.39M | +596.2% | +9.4% |
| June 30, 2023 | $157.64M | +84.3% | +25.1% |
- Jazz Pharmaceuticals plc showed a decrease of -160.0% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Jazz Pharmaceuticals plc’s operating income has declined by 2800.8% (from $15.93 million to -$430.24 million).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: